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Abstract.  Mice with a targeted mutation in the myo- 
genic basic helix-loop-helix regulatory protein myoge- 
nin have severe  muscle defects resulting in perinatal 
death. In this report, the effect of myogenin's absence 
on embryonic and fetal development is investigated. 
The initial events of somite differentiation occurred 
normally in the myogenin-mutant embryos. During 
primary myogenesis, muscle masses in mutant em- 
bryos developed simultaneously with control siblings, 
although muscle differentiation within the mutant mus- 
cle masses was delayed. More dramatic effects were 
observed when secondary myofibers  form. During this 
time, very little muscle formation took place in the 
mutants, suggesting that the absence of myogenin 
affected secondary myogenesis more severely than pri- 
mary myogenesis. Monitoring mutant neonates with 
fiber type-specific myosin isoforms indicated that 
different fiber types were present in the residual mus- 
cle. No evidence was found to indicate that myogenin 
was required for the formation of muscle in one region 
of the embryo and not another. The expression pat- 
terns of a MyoD-lacZ transgene in myogenin-mutant 
embryos demonstrated that myogenin was not essential 
for the activation of the MyoD gene. Together,  these 
results  indicate that late stages  of embryogenesis are 
more dependent on myogenin than early stages, and 
that myogenin is not required for the initial aspects  of 
myogenesis, including myotome formation and the ap- 
pearance of myoblasts. 
S 
KELETAL  muscle in vertebrates originates from somitic 
mesoderm as  pluripotent  mesodermal  cells  become 
committed to a myogenic fate. Committed myoblasts 
populate areas throughout the developing embryo, ultimately 
differentiating into bundles of  multinucleate myofibers. Four 
key players in myogenic events are the basic helix-loop-helix 
(bHLH) ~  regulatory proteins: MyoD, Myf5, myogenin, and 
MRF4 (for recent reviews see Emerson,  1993; Weintraub, 
1993; Olson and Klein,  1994). These muscle-specific tran- 
scription factors are individually able to initiate the entire 
muscle differentiation program when introduced into tissue 
culture  cells  of nonmuscle  origin.  Using  gene-knockout 
technology, several laboratories  have created mice lacking 
functional myogenic bHLH factors and are now providing 
useful  models  for  studying  skeletal  muscle  development 
(Braun et al.,  1992; Rudnicki et al.,  1992; 1993; Hasty et 
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al., 1993; Nabeshima et al., 1993). To date, null mutations 
in three of the four myogenic bHLH factors (MyoD, Myf5, 
and myogenin) have been analyzed. 
Null mutations in MyoD or Myf5 result in no observable 
muscle abnormalities, though unexpectedly, Myf5 mutants 
are missing the distal portions  of their ribs  (Braun et al., 
1992; Rudnicki et al.,  1992). Because studies with tissue 
culture cells strongly implicate MyoD and Myf5 as impor- 
tant regulators of muscle development, the results suggest 
functional  overlap  among  the  myogenic factors.  Indeed, 
cross-breeding MyoD- and Myf5-mutant  mice to create dou- 
ble  mutants  has  demonstrated  that MyoD and Myf5  can 
compensate for each other (Rudnicki et al.,  1993). Muta- 
tions in both MyoD and Myf5 prove to be lethal at birth and 
produce a strong muscle phenotype. These mice lack skele- 
tal muscle and do not have discernable myoblasts. Thus, the 
MyoD/Myf5-mutant mice are unable to initiate myogenesis. 
Myogenin-mutant  mice  are  born  with  severe muscle 
deficiency, although  less  severe than  MyoD/Myf5-mutant 
mice,  and they die within minutes of birth  (Hasty et al., 
1993; Nabeshima et al., 1993). All regions that are normally 
populated  by multinucleate  muscle  fibers instead  contain 
large numbers of mononucleate cells and a reduced number 
of myofibers. The residual myofibers have an apparent nor- 
mal morphology, indicating that some myogenic differentia- 
tion occurs. Although myogenin is normally expressed be- 
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normal levels of MyoD transcripts, suggesting that myogenin 
is not required for MyoD expression. Surprisingly, while the 
presence of MyoD in mutant mice is not sufficient for myo- 
blast differentiation, myogenin-mutant myoblasts differenti- 
ate into seemingly normal myotubes when cultured in vitro 
(Nabeshima et al.,  1993; Rawls,  A.,  D.  Edmondson,  and 
E. N.  Olson,  unpublished results).  The myogenin-mutant 
mice provide direct evidence for myogenin's essential role in 
skeletal muscle development in vivo but not in vitro. 
Comparisons of myogenin-mutant mice with MyoD/Myf5 
mutants  suggest  a  genetic hierarchy  whereby  MyoD and 
Myf5 act upstream of myogenin and are likely to have redun- 
dant functions associated with early events of myoblast for- 
mation (Weintraub, 1993; Rudnicki et al.,  1993; Olson and 
Klein,  1994). Myogenin is probably involved in the subse- 
quent downstream events required for differentiation of myo- 
blasts into myotubes. MRF4 may function similarly to myo- 
genin  or  may  lie  further downstream  in  the  pathway  to 
control later events associated with myofiber formation. 
Our initial characterization of the myogenin-mutant mice 
was based almost entirely on the phenotype of mutant neo- 
nates,  and  it did not directly address  the muscle-forming 
ability of these mice during embryogenesis.  In  wild-type 
mice, myogenin transcripts are expressed in the myotome on 
day 8.5, '~0.5 d after Myf5 and 2 d before MyoD (Sassoon, 
1993; Smith et al.,  1993). It is not known if the absence of 
myogenin affects the formation of the myotome, the somitic 
compartment responsible for producing myoblasts, or if the 
initial expression of the bHLH factors is altered. 
Myogenesis occurs as  two sequential  waves,  a  primary 
wave beginning on about day 12.5 and a secondary wave be- 
ginning on about day 15.5 (Kelly, 1983). It is possible that 
the bHLH myogenic factors have different roles  in  these 
processes.  Similarly, these factors may be associated with 
fiber-type specialization, which occurs during fetal develop- 
ment (Buckingham,  1992). In an earlier report, we specu- 
lated  that  the  residual  myofibers  observed  in  myogenin- 
mutant mice may correspond to a particular fiber type, and 
that  myogenin is  essential  for certain fiber types but not 
others. 
Here, we describe the embryonic phenotype of the myo- 
genin-mutant mice. We show that the initial events of somitic 
differentiation are  normal  in  the mutants,  and  that  while 
muscle masses in developing mutant and wild-type embryos 
develop simultaneously, cells in the masses do not express 
muscle-specific markers at the same time and to the same ex- 
tent. Moreover, the organization of tissue in the developing 
muscle masses is distinct in mutant and wild-type embryos 
with fewer differentiated myocytes in the mutants. The major 
differences between mutant and wild-type embryos becomes 
apparent  during  the  time  when  secondary  myofibers are 
forming, suggesting that the absence of myogenin may affect 
secondary myogenesis more severely than primary myogene- 
sis. We find no evidence that the residual myofibers formed 
in the mutants correspond to a particular myofiber type or 
that myogenin is required for the formation of muscle in a 
particular  region of the  embryo.  Finally,  we  show  that  a 
MyoD-lacZ transgene present in a myogenin-mutant genetic 
background  is  activated  normally  in  myotomes  on  em- 
bryonic day  10.5, and  that  MyoD  is  expressed  normally 
throughout development. 
Figure 1.  Somite and  early  muscle development in  myogenin- 
mutant embryos. The differentiation of somites into the derma- 
tome, myotome, and sclerotome occurred on schedule and with 
normal morphology in both wild-type (A) and myogenin-mutant 
embryos (B) at 10.5 d postcoitum. The arrowhead marks the myo- 
tome compartment; above  and below the myotome are the derma- 
tome and sclerotome compartments, respectively. At 12.5 (C and 
D) and 14.5 d (E and F), embryos show comparable morphology 
over muscle forming regions lateral to the neural tube (arrow). At 
18.5 d (G and H), differences are observed in corresponding mus- 
cle regions between wild-type and mutant embryos (arrow). 
Materials and Methods 
Animals and Genotyping of  Embryos 
Mice heterozygous for the myogenin-null mutation were generated as de- 
scribed in Hasty et al. (1993).  Mice were genotyped by Southern blot hy- 
bridization of genomic DNA prepared from tails of neonates and yolk sacs 
of  embryos using a 900-bp EcoRI/SstI fragment of mouse myogenin eDNA 
as probe and EcoRI-digested genomic DNA (Hasty et al.,  1993).  MyoD- 
lacZ transgenic mice, generated as described by Goldhamer et al. (1992), 
were obtained from Moshe Shani (The Volcani Center, Bet Dagan, Israel) 
and crossed with myogenin-mutant mice to generate mice that were doubly 
heterozygous for both the MyoD-lacZ  transgene and myogenin. The double 
heterozygotes were then crossed to generate mice that were homozygous for 
the myogenin mutation and also carried the MyoD-lacZ transgene. 
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Tissue Preparation 
Embryos were fixed in 4% paraformaldehyde and embedded in paraffin for 
both indirect immunofluorescence and nucleic acid in situ hybridization 
analyses on sections through whole embryos (Lyons et al., 1990). Embryos 
older than  16 d  of development and neonates were  skinned to  facilitate 
penetration and infiltration. Transverse sections were cut at 6 #m, and for 
each time point, parallel sections of mutant and control siblings from the 
same litter were placed on the same slide. 
Frozen sections through hindlimbs were used to identify different myosin 
isoforms in neonates by indirect immunofluorescence.  Hindlimbs from neo- 
nates were frozen rapidly in isopentane cooled to -60°C in liquid nitrogen 
and mounted for sectioning. Frozen sections were cut at 10/~m and stored 
at  -10°C.  Sections through approximately the same level in mutant and 
nonmutant hindlimbs were examined by indirect immunofluorescence for 
the expression of myosin heavy chain (MHC)  isoforms. 
Immunohistocheraistry 
For the analysis of MHC and desmin protein expression, sections through 
embryos were deparaliinized in two changes of 100%  xylene for  10 min 
each. The xylene was then removed and sections gradually introduced to 
PBS by sequential 10-rain incubation through 1:1 xylene/methanol, 100% 
methanol,  1:1  methanol/PBS, and finally  100%  PBS.  The sections were 
then blocked for a minimum of 30 min in 3 % normal goat serum diluted 
in PBS. Incubations in both primary and secondary antibodies were for a 
minimum of 1 h, and the antibodies were washed from the sections after 
each antibody incubation by three 10-min washes with PBS. A monoclonal 
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antidesmin antibody was diluted 1:20 in PBS. Antibodies were purchased 
from Sigma Immunochemicals (St.  Louis,  MO).  Secondary antibodies 
were FITC-conjugated goat anti-mouse (Sigma Immunoehemicals) diluted 
hl00  in  PBS  and  tetramethylrhodamine isothiocyanate-conjugated goat 
anti-rabbit (Cappel-Organon-Teknika, West Chester, PA) diluted 1:200 in 
PBS. After the final washes, slides were mounted in FITC-Guard  TM (Testog, 
Inc., Chicago, IL). 
Indirect immunofluorescence of frozen sections with monoclonal anti- 
bodies to different  MHC isoforms was used to compare fiber types in mutant 
and nonmutant neonate limbs (Condon et al., 1990).  Essentially, slides of 
frozen sections were incubated in 0.2% BSA in PBS (PBS-BSA) for 30 rain 
and then in primary antibody diluted in PBS-BSA overnight at 4°C in a hu- 
mid chamber. The slides were then rinsed five times with ice-cold PBS, then 
washed three times for 5 min each in ice-cold PBS-BSA. Secondary incuba- 
tions were for 1 h at 4"C in a humid chamber in the goat anti-mouse, FITC- 
conjugated antibody described above. The sections were rinsed and washed 
again (as described above) and mounted in FITC-Guard  TM. The primary anti- 
bodies used were monoclonal antibodies to slow (4A.840)  and embryonic 
MHC (FI.652), as detailed by Condon et al. (1990),  and antiskeletal fast 
MHC (MY-32). 
In Situ Hybridization 
In situ hybridization using mnscle-specific markers was performed as de- 
scribed in Lyons et al. (1990).  The MHCemb and MHCpn riboprobes were 
described in Lyons et al. (1990).  MyoD sense and antisense riboprobes were 
transcribed from a  full-length cDNA as described in Edmondson et al. 
(1994).  6-t~m transverse sections through embryos at approximately the 
same anatomical level were positioned on slides, such that mutant and non- 
mutant siblings were exposed to identical conditions. Parallel slides labeled 
with sense riboprobes corresponding to each antisense probe showed no 
specific labeling above background. 
Detection of Vascular Cell Adhesion 
Molecule-I (VCAM-I) Transcripts by Reverse 
Transcription PCR (RT-PCR  ) 
Total RNA was isolated from either fore- and hindlimb or carcass (internal 
organs and head removed) at different developmental stages from myogenin- 
mutant and heterozygous embryos as previously described (Hasty et al., 
1993).  1/xg of RNA per reaction was used to synthesize cDNA using ran- 
dom primers and reverse transcriptase (Boehringer Mannheim Biochemi- 
cals, Indianapolis, IN) according to the manufacturer's specifications. One 
tenth of this reaction was then used for PCR using 100 ng of each of the 
primers described below, 1/~Ci of [a32P] dCTE and 1.5 mM MgCI2. PCR 
amplification conditions were 94°C for 1 rain, 60°C for 1 rain, and 72°C 
for 1 min for 23 cycles. This cycle number was chosen to keep the yield 
of the PCR product proportional to the mRNA abundance. For VCAM-I 
amplification,  the  primers  were  ACACTTTTCCCAGACACTTTTCACG 
(nucleotides  1374-1398)  and  AG~TGTCTATCTGGGTTCTCC 
(nucleotides 2093-2117)  (Cybulsky et al., 1993),  giving a predicted band 
of 235 bp. One tenth of this reaction was then fractionated on a 6% poly- 
acrylamide gel and visualized by autoradiography. To control for variation 
of RNA into each reaction, ribosomal protein L7 mRNA levels were ana- 
lyzed using identical PCR conditions and previously described primers 
(Hollenberg et al.,  1993). 
X-Gal Staining 
To observe expression pattern of the MyoD-lacZ  transgene in the myogenin- 
mutant background, litters of embryos from matings between mice doubly 
heterozygous for the myogenin-null mutation and the MyoD-lacZ  transgene 
were killed at different embryonic stages and stained as whole mounts for 
~3-galactosidase  activity (Cheng et al.,  1993). 
Results 
Somite Development and Development of  Muscle 
Masses in Myogenin-Mutant Embryos 
Between days 8.5 and 10.5 in mouse development, somites 
compartmentalize  into  the  dermatome,  myotome,  and 
sclerotome.  We compared identical somitic regions from 
wild-type and myogenin-mutant embryos at 9.5  and  10.5 
days, a time when the myogenin gene is first activated, and 
found no significant morphological differences. For exam- 
pie, the three regions of a somite comprising the dermatome, 
myotome, and sclerotome appeared normal in a mutant em- 
bryo (Fig.  1 B) when compared to a wild-type embryo at 
10.5 d (Fig. 1 A). These results suggest that somites can form 
at the proper time and with normal morphological features 
in the absence of myogenin activity. 
From 10.5 to  14.5  d of embryonic development, hema- 
toxylin-eosin-stained sections  of  embryos  revealed  little 
difference between the muscle-forming regions of wild-type 
and mutant embryos (Fig.  1, C-F). After 15.5 d, however, 
the muscle-forming regions in mutant embryos was greatly 
reduced in mass compared to those of wild-type siblings 
(Fig.  1, G and H). These results suggest that at least initially, 
the muscle-forming regions contained cells with myogenic 
potential, and that this potential is lost in the myogenin mu- 
tants as development proceeds. 
Appearance of  Muscle-specific Gene Products in 
Myogenin-mutant Embryos 
We collected embryos from the time muscle masses are first 
morphologically distinguishable (day 12.5) until birth, and 
we analyzed them for the appearance of MHC. On day 12.5, 
sections through wild-type embryos labeled with the MHC 
antibody showed evidence of developing myofibers through- 
out muscle-forming masses (Fig. 2, 12.5 d, +/+). Identical 
sections of 12.5-d mutant embryos also stained for MHC in- 
dicated that muscle masses were present to the same extent, 
but the staining was significantly weaker, and the cells that 
stained appeared less organized (Fig. 2, 12.5 d, -/-). Simi- 
lar results were observed on day 15.5. At this time, well- 
differentiated myofibers were detected with the MHC anti- 
body in wild-type embryos, whereas in mutant embryos, the 
same areas labeled, but less intensely, and myofibers were 
more diffuse (Fig. 2, 15.5 d,  +/+  vs  -/-).  Between 15.5 
d and birth, there was a dramatic increase in myofiber num- 
ber and intensity of MHC labeling in the wild-type embryos 
(Fig. 2, 16.5 d and Neonate). It is during this time interval 
that major differences between wild-type and mutant em- 
bryos became most apparent. Mutant 16.5-d-old embryos or 
neonates showed the presence of myofibers, but their num- 
bers and their levels  of MHC expression were greatly re- 
duced with respect to their wild-type counterparts. 
To extend these results, we made use of  an antibody against 
desmin, an intermediate filament protein that is expressed 
early  in  the  myogenic pathway (George-Weinstein  et  al., 
1993). At 12.5 d, muscle masses from the dorsal regions of 
mutant embryos contained intensely labeled desmin-positive 
cells, while the same section showed only weak MHC label- 
ing when compared with controls (Fig. 3, 12.5 d, back, +/- 
vs -/-).  Wild-type muscle masses showed both desmin and 
MHC-labeled cells in limbs at 12.5 d, but the mutant showed 
only weak desmin staining and no detectable MHC (Fig. 3, 
12.5 d, limb, +/- vs -/-).  These results suggested that the 
mutant embryos lagged behind their wild-type siblings in the 
differentiation of myoblasts in premuscle masses. 
As development proceeded, cells exhibiting intense des- 
min staining were consistently observed at the periphery of 
wild-type muscle masses in both the back and hindlimbs and 
elsewhere in the body (Fig.  3,  14.5 d, back, limb, +/-). 
The Journal of Cell Biology,  Volume 128, 1995  566 Figure 2.  Comparison of MHC expression  in myogenin-mutant  and wad-type embryos.  Discrete  MHC-positive ceils were detectable in 
the back region of nonmutant embryos as early as day 12.5. In mutant embryos, the same muscle-forming regions could be discerned, 
but the level of MHC expression was reduced and MHC staining was seen in fewer cells.  As development continued, increased MHC 
expression was observed in nonmutants, but comparable levels of MHC expression were never achieved in the myogenin mutants. While 
the most comparable levels of MHC protein expression  were seen on day 15.5; thereafter,  nonmutant 16.5-d-old embryos and neonates 
showed a dramatic increase  in the number of cells expressing MHC, whereas  16.5-d-old mutant embryos and neonates failed to exhibit 
a similar increase,  nt, neural tube; drg, dorsal  root ganglia;  V, vertebral body. Left column, +/+; right column,  -/-. The Journal of Cell Biology, Volume  128, 1995  568 Figure 4. Embryonic and perinatal MHC transcript accumulation during embryogenesis in myogenin-mutant and wild-type embryos. De- 
tectable levels of transcripts for embryonic MHC are observed in nonmutant (A) and mutant (B) embryos during early embryonic stages 
as shown here for day 14.5. On day 18.5, the perinatal isoform of MHC showed that the level of MHC expression in the mutants (D) was 
greatly reduced compared to that seen in nonmutant siblings (C). The intense labeling seen in C and D over the liver and heart are refraction 
artifacts. 
Figure  3.  Desmin expression in myogenin-mutant and wild-type embryos. Antibodies to MHC (green)  and desmin (red).  On day 12.5, 
the back and limb muscle-forming regions of the nonmutants showed distinct labeling of cells by both muscle markers, whereas comparable 
regions in mutant embryos showed only weak desmin staining in the back and even weaker staining in the limbs. MHC labeling in mutant 
embryos at this stage was extremely weak. On day 14.5, the level of expression of both antigens increased dramatically in back and limb 
muscle-forming regions of  both mutant and nonmutant embryos. The organization of desmin-positive  cells in the mutant back and hindlimb, 
however,  more closely resembled that of the immature back and limb seen in nonmutants on day 12.5. Desmin-positive cells in the back 
and limbs in the nonmutants were found in the periphery of the muscle groups (arrows).  N, neural elements that are also recognized by 
the desmin antibody). Le3~ column,  +/-;  right column,  -/-. 
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aligning within the developing muscle. In contrast, mutant 
embryos  showed  a  greater  number  of intensely  stained 
desmin-positive cells  that  were  scattered  throughout the 
muscle masses (Fig.  3, 14.5 d, back, limb, -/-)  and ap- 
peared as myoblasts that persisted in the mutant muscle- 
forming regions.  These  results provided further evidence 
that the myogenic process was initiated in mutant embryos, 
but complete muscle differentiation  did not occur. The orga- 
nization  of  desmin-positive  cells  in  the  mutant  muscle 
masses of later embryos resembled that seen in the muscle 
masses of younger mutant embryos,  suggesting that myo- 
blasts are blocked in their ability to differentiate. 
In early embryogenesis, MHC is first expressed as an em- 
bryonic isoform, which then switches to a perinatal form on 
day 16.5 (Lyons et al.,  1990).  We used riboprobes specific 
to  untranslated regions  of embryonic or perinatal  MHC 
mRNAs to determine if the MHC embryonic-to-perinatal 
switch took place normally in the myogenin mutants. Up to 
day 14.5,  wild-type and mutant embryos displayed detect- 
able signals in muscle-forming regions using the embryonic 
probe (Fig. 4, A and B). As observed with the MHC anti- 
body,  labeling of muscle masses  in mutant embryos was 
generally less intense, suggesting that muscle differentiation 
was perturbed. By day 18.5, the embryonic probe yielded 
only very low signals with either wild-type or mutant em- 
bryos, suggesting that appropriate downregulation of  the em- 
bryonic MHC variant had occurred (not shown). When day 
18.5 embryos were probed with the perinatal form of MHC, 
dramatic differences were observed between wild-type and 
mutant embryos (Fig. 4, C and D). While the wild-type em- 
bryos  produced  an  intense  signal  over  muscle-forming 
regions, mutant embryos showed very weak signals. The rel- 
ative differences in signal intensity were largely attributable 
to a deficiency of  muscle in the mutants at this developmental 
stage. These results further supported the notion that up to 
15.5  d,  muscle  masses  were  capable  of forming  in  the 
myogenin-mutant mice, but after that time, while wild-type 
embryos underwent extensive muscle formation, mutant em- 
bryos were severely impaired. 
Expression  of VCAM-1 in Myogenin-mutant Embryos 
A  possible  explanation  for  the  defects  observed  in  the 
myogenin-mutant mice at later stages is the inability of sec- 
ondary myoblasts to fuse. The integrin VLA-4 and its coun- 
terreceptor, VCAM-1, have been implicated in the process of 
alignment and fusion of secondary myoblasts (Rosen et al., 
1992). In particular, VCAM-1 is expressed at sites of second- 
ary myogenesis (Rosen et al., 1992).  A lack of VCAM-1 ex- 
pression in mutant embryos would suggest that secondary 
myoblasts would be deficient in fusion. We used RT-PCR to 
monitor the expression of VCAM-1 in wild-type and mutant 
embryos. VCAM-1 transcripts were expressed at approxi- 
mately equal levels  in limbs of wild-type and mutant em- 
bryos at  13.5 d  (Fig.  5,  lanes  1 and 2).  Levels increased 
slightly at 14.5 d in both wild-type and mutant limb muscle 
(Fig. 5, lanes 3 and 4). RNA isolated from carcasses, which 
includes all muscle regions, again showed equal VCAM-1 ex- 
pression in wild-type and mutant embryos (Fig. 5, lanes 5 
and 6).  By  16.5 d,  VCAM-1 expression decreased some- 
what, but no significant differences were found between the 
wild-type and mutants (lanes 7 and 8). These results demon- 
Figure 5.  Expression of VCAM-1 in myogenin-mutant embryos. 
The level of VCAM-1 mRNA in limb muscle from 13.5- and 14.5-d- 
old embryos, and carcass from 14.5- and 16.5-d-old embryos was 
examined by RT-PCR analysis (top row). Omission of the reverse 
transcriptase from the reaction resulted in no amplification (not 
shown). RNA loading was assessed by ribosomal L7 transcript lev- 
els  (bottom row). het and rout, heterozygous and  homozygous 
myogenin-mutant  embryos, respectively. 
strate that VCAM-1 expression  is not affected by the absence 
of myogenin. Moreover, the presence of normal levels  of 
VCAM-1 are not sufficient for secondary myoblast fusion. 
Lack of  Regional Differences in Muscle Formation in 
the Myogenin-mutant Mice 
Nabeshima et al. (1993) reported that in myogenin-mutant 
embryos  there  is  a  difference  in  the  degree  of  muscle 
differentiation in the myotome vs the limb and body wall. 
The myotomal cells are derived from differentiation  of myo- 
blasts in situ, whereas the myoblasts that populate the limbs 
and elsewhere migrate from the dermamyotome and colo- 
nize the muscle-forming regions. It has been proposed that 
different myogenic lineages arise from the somite, and that 
the different bHLH myogenic factors play a role in defining 
these lineages (Ordahl and Le Douarin,  1992).  Although 
some differences in the extent of muscle differentiation were 
evident in different regions of the mutant embryos during 
early stages of development (not shown), by  18.5 d,  this 
difference was no longer apparent, and the extent of muscle 
deficiency seen in the back, body wall, and limbs was com- 
parable. Thus, as monitored by MHC antibodies, muscles in 
the back, ventral-lateral body wall, and forelimb of 18.5-d- 
old mutant embryos all showed far fewer muscle fibers than 
seen in comparable regions of control littermates (Fig. 6; A, 
C, and E vs B, D, and F). These results argue against the hy- 
pothesis that myogenin function is more essential for ter- 
minal differentiation of nonmyotomal-derived muscles.  A 
likely explanation for the difference between these results 
and those of Nabeshima et al. (1993) is that the latter study 
only analyzed 14.5  d-old embryos, a time when delays in 
the differentiation of limb and ventral body wall muscle in 
myogenin mutants are apparent. 
Myogenin-mutant Neonates Express Both Fast and 
Slow MHC lsoforms 
To  assess  the  properties  of the residual  myofibers in  the 
myogenin-mutant neonates, we made use of antibodies that 
distinguished between embryonic, fast, and slow MHC iso- 
The Journal of Cell Biology, Volume  128, 1995  570 Figure 6. Lack of regional differences in the density of residual myofibers in the myogenin-mutant embryos. Antibodies to MHC demon- 
strate that the muscle deficiency was as severe in the back region (A and B) as it was in the ventral body wall (C and D) and limbs (E 
and F) of mutant embryos compared with similar regions in nonmutants. 
forms (Condon et al.,  1990). As expected, sections through 
hindlimbs  of  wild-type  neonates  demonstrated  a  higher 
proportion of fibers labeled with antibody to fast MHC than 
to slow MHC (Fig. 7, +/+). When the same antibodies were 
used to label mutant hindlimbs, a similar ratio of fast vs slow 
anti-MHC-labeled fibers was observed (Fig. 7, -/-).  Thus, 
both fiber types could still form, despite the absence of myo- 
genin. 
Surprisingly, all the different muscle groupsthat compose 
the crural region were evident in the mutant hindlimb, albeit 
with reduced fiber number (Fig. 7, A-C). The overall num- 
ber of muscle fibers in the mutant limbs, however, was con- 
siderably reduced compared to the number seen in wild-type 
limbs.  These  results,  together  with  those  obtained  from 
MHC labeling through sections of whole embryos, suggested 
that the formation of myogenic precursors in the myogenin- 
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tion and differentiation of these precursors was abnormal. 
Expression of the MyoD Gene in 
Myogenin-mutant Embryos 
In an earlier  study, we  showed that MyoD transcripts in 
myogenin-mutant neonates were present at similar levels as 
in wild-type, and that on day 14.5, MyoD protein was present 
at normal levels (Hasty et al., 1993).  These results did not 
address whether the MyoD gene was activated at the appro- 
priate time and place in the absence of myogenin, and if its 
mRNA accumulated in a normal fashion. To answer the lat- 
ter question,  we  followed MyoD transcript accumulation 
through embryogenesis using in situ hybridization with a 
MyoD-specific antisense riboprobe. 
MyoD transcript levels were similar in mutant and wild- 
type embryos on embryonic days 12.5  and  14.5  (Fig.  8). 
MyoD expression appeared normal in all muscle-forming 
regions of the  mutant embryos where,  presumably,  tran- 
scripts were accumulating in myoblasts and differentiating 
myofibers (+/+  vs  -/-  on day 12.5 and +/-  vs -/-  on 
day  14.5).  Similarly, at later stages of development (18.5 
days and neonates), no obvious difference in the levels of 
MyoD expression were observed between mutant and wild- 
type embryos (not shown). 
Since myogenin transcripts are detected 2 d before those 
of MyoD (Smith et al.,  1993),  myogenin's absence could 
affect the initial activation of  the MyoD gene. To address this 
question, we cross-bred the myogenin-mutant mice with a 
transgenic line harboring a MyoD-/acZ fusion gene capable 
of expressing lacZ with the same temporal and spatial pat- 
terns  as  the endogenous MyoD gene (Goldhamer et al., 
1992).  Mice heterozygous for the myogenin mutation and 
hemizygous or homozygous for the MyoD-lacZ transgene 
were mated with one another to produce embryos deficient 
in  myogenin,  and  hemizygous  or  homozygous  for  the 
transgene. 
On day 10.5, cells in the myotomal compartments of  all so- 
mites labeled with approximately equal intensity in both mu- 
tant and control embryos (Fig. 9, 10.5 d,  -/-  vs +/-). As 
development proceeded,  MyoD-lacZ expression extended 
from  the  somitic  region  into  all  major  muscle-forming 
regions of the embryo so that at 11.5 d, expression was seen 
in trunk, body wall, limb, and facial muscles of both mutant 
and wild-type embryos (Fig. 9, 11.5 d,  -/-  vs  +/-).  By 
13.5 d, labeling was as intense in the mutant embryos as in 
the wild-type controls, although the muscle masses through- 
out the mutants were more disorganized, indicating the pres- 
ence of large numbers of undifferentiated myoblasts (Fig. 9, 
13.5 d, -/-  vs +/-). From these results, it is clear that my- 
ogenin is  not required  for either the  activation or main- 
tenance of MyoD gene expression. 
Discussion 
Our analysis of the myogenin-mutant phenotype during em- 
bryogenesis  extends  our  initial  characterization  of these 
mice, and it demonstrates that myogenin plays an essential 
role in skeletal muscle development from the time muscle 
masses first appear until birth. An intriguing feature of the 
myogenin-mutant  mice is that they are capable of generating 
semblances of differentiated muscle during embryogenesis. 
Our results clearly show that "myogenic"  cells are present in 
myogenin-mutant embryos. An unexpected finding showed 
that mutant and wild-type embryos appear more similar in 
their myogenic regions between 9.5 and 15.5 d than between 
15.5 d and birth. The initial wave of myogenesis occurs be- 
tween 10.5 and 14.5 d, and it results in the initial appearance 
of myofibers in most regions of the embryo (Kelly, 1983). In 
the myogenin-mutant embryos, muscle masses, which cor- 
respond  to  areas  where  mature  muscle  will  ultimately 
differentiate, are capable of some differentiation, but they are 
clearly abnormal in both their morphological features, as 
well as patterns of MHC and desmin expression. Neverthe- 
less, the absence of myogenin did not prevent at least some 
remnants of muscle differentiation from occurring at these 
early times,  arguing  that myoblasts can  align,  fuse,  and 
differentiate normally.  These  findings indicate that some 
myogenic cells may be capable of differentiating along the 
myogenic pathway through a myogenin-independent mech- 
anism. 
It is only after day 14.5 that dramatic differences appear 
between the myogenin-mutant and wild-type embryos. This 
is the time when secondary myogenesis  occurs (Kelly, 1983). 
The increase in the number of myofibers in wild-type em- 
bryos is the result of the differentiation of myoblasts that are 
associated with the primary myofibers and subsequent fusion 
of these cells to produce extensive myofiber bundles. Our 
data demonstrate that this process is severely retarded in the 
myogenin-mutant mice, and may not take place at all. The 
particular defect that prevents the differentiation  of  myoblasts 
to form secondary myotubes is not well understood. We sug- 
gest from these results that myogenin affects both primary 
and  secondary  myogenesis,  but  that  its  role  in  the  two 
processes  may not be  identical.  Regulatory factors other 
than myogenin may compensate somewhat for the loss of 
myogenin during primary myogenesis. In contrast, second- 
ary myofibers may require myogenin-dependent  activation of 
a specific set of genes that cannot be activated by other myo- 
genic regulators. 
It has been proposed that secondary fiber formation is de- 
pendent on the number of primary myofibers that form, and 
alternatively, that secondary myogenesis is dependent on in- 
nervation of  primary myotubes (Condon et al., 1990; Wilson 
and Harris,  1993).  One theory argues that denervation re- 
duces the number of primary fibers that are formed, which 
leads to reduced secondary fiber formation (Condon et al., 
1990).  The opposing theory argues that primary myotubes 
form autonomously, and denervation specifically affects sec- 
ondary myotube formation (Wilson and Harris, 1993). Both 
theories argue that innervation plays a role in muscle devel- 
opment.  Relevant to this,  we have shown that myogenin- 
mutant mice do not make detectable levels  of the tx and 
"y-subunits of the acetylcholine receptor (Hasty et al., 1993), 
Figure 7. Detection of fast and slow isoforms  of MHC in the limbs of myogenin-mutant  and wild-type neonates. Sections  through hindlimbs 
of neonates with antibodies specific to different isoforms of MHC revealed that mutant hindlimbs contained myofibers  that expressed both 
fast and slow isoforms  of MHC in a ratio comparable to that seen in wild-type embryo hindlimbs. In addition, the mutant hindlimbs showed 
many of the same muscle groups that were present in wild-type hindlimbs (labeled A, B, and C for comparison), t, tibia; f, femur. 
Venuti et al. Myogenin during Mouse Development  573 Figure 8.  Accumulation of MyoD transcripts in myogenin-mutant and wild-type embryos. Comparable levels of expression of transcripts 
were seen in both wild-type and mutants at early embryonic stages (day 12.5 and 14.5). As development progressed, the levels of expression 
decreased in both the wild-type and mutant with slightly lower levels observed in mutants after 16.5 d. nt, neural tube. 
which would lead to an absence of receptors on the cell sur- 
face and an inability to make proper nerve connections. 
An additional feature of the myogenin-mutant phenotype 
is the presence of residual myofibers with seemingly normal 
morphology in late-stage embryos and neonates. These re- 
sidual fibers reflect a normal ratio of physiologically distinct 
fiber types. A recent report presents evidence that MyoD ex- 
pression is associated with slow-twitch fiber types and myo- 
genin with fast-twitch fiber types in adults (Hughes et al., 
1993), but if so,  such differential expression is not mani- 
fested in the myogenin-mutant embryos. 
From the results presented here and  from our previous 
analysis (Hasty et al.,  1993), it is apparent that MyoD ex- 
pression is unaltered in myogenin's absence. Of course, this 
does not prove that myogenin does not regulate the MyoD 
gene in wild-type mice, since other myogenic factors, partic- 
ularly Myf5, may compensate for the loss of myogenin. Re- 
cent evidence shows that Myf5 expression also appears to be 
unaffected in the myogenin mutants (Rawls,  A., and E. Ol- 
son, unpublished results). Furthermore, the embryonic ex- 
pression of a myogenin-/acZ  transgene containing the appro- 
priate control region of the myogenin gene is  identical in 
The Journal of Cell Biology, Volume  128, 1995  574 l~gure  9.  Expression  of a  MyoD-/acZ transgene  in  myogenin- 
mutant embryos. Comparable levels of staining were seen in the so- 
mites of 10.5-d-old nonmutant and mutant embryos. (The slight 
difference between the wild-type and mutant embryos seen in the 
figure is variable and not significant). Similar levels of expression 
were  also  seen  as development continued  such that  nonmutant 
and mutant embryos were almost indistinguishable at 11.5 d. At 
later  stages, differences in  expression became  apparent  as  the 
mutant  embryos  showed a  lesser  degree  of organization of the 
/3-galactosidase-positive cells  into  organized myofibers than did 
their nonmutant siblings. This can be seen as more diffuse staining 
throughout the body of  the mutant embryo when compared with the 
wild-type embryo, particularly along the posterior-dorsal regions. 
wild-type and myogenin-mutant backgrounds (Cheng et al., 
1995).  Hence, myogenin is not essential for regulating its 
own gene, nor the genes for Myf5 or MyoD. Interestingly, 
the  only bHLH myogenic factor that  may be  affected is 
MRF4, whose transcripts are dramatically reduced in myo- 
gem-mutant neonates (Hasty et al.,  1993). 
MyoD and Myf5 appear to have redundant functions, and 
they  lie upstream  of myogenin in  the  myogenic pathway 
(Weintranb, 1993; Rudnicki et al.,  1993; Olson and Klein, 
1994). It has also been hypothesized that MRF4 lies down- 
stream of myogenin. Thus, MyoD and Myf5 may act directly 
to control the expression of myogenin, as evidenced by the 
lack of myogenin in MyoD/Myf5-mutant mice (Rudnicki et 
al.,  1993). In contrast, MyoD and Myf5 expression is un- 
altered in the myogenin-mutant mice, whereas the MRF4 
gene appears not to be expressed. This implies that MyoD 
and Myf5 are responsible for early events of  myoblast forma- 
tion,  including the activation of myogenin.  Myogenin,  in 
turn, is responsible for later events associated with myotube 
differentiation, including the activation of MRF4.  Finally, 
MRF4 may be responsible for the final myogenic events of 
the fully differentiated myofiber. A testable prediction from 
this model is that the myogenic bHLH factors activate differ- 
ent sets of target genes during muscle development, and that 
the activation of these sets follows a  precise temporal se- 
quence as myoblasts begin their differentiation program. 
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